Effects of Therapy with [177Lu-DOTA0, Tyr3]Octreotate in Patients with Paraganglioma,

Therapy using the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate) (DOTA is 1,4,7,10-tetraazacyclododecane-N,N9,N99,N999-tetraacetic acid) has been used primarily in gastroenteropancreatic neuroendocrine tu-mors. Here we present the effects of this therapy in a small num-ber of patients with metastasized or inoperable paragangliomas, meningiomas, small cell lung carcinomas (SCLCs), and melano-mas.Methods: Twelve patients with paraganglioma, 5 with me-ningioma, 3 with SCLC, and 2 with eye melanoma were treated. Three meningiomas were very large and exophytic and all stan-dard treatments had failed. Patients with melanoma had rapidly progressive disease (PD). The intended cumulative dose of 177Lu-octreotate was 22.2229.6 GBq. Effects of the treatment on tumor size were evaluated using the Southwest Oncology Group criteria. Results: Two of 4 patients with progressive para